HEALTH

DEERFIELD, Ill. — Baxter International on Tuesday announced results of a study published in this week's issue of The Lancet that demonstrated effectiveness and tolerability of the company’s Preflucel in protecting against seasonal influenza.

ALEXANDRIA, Va. — Lansinoh Labs on Tuesday announced the acquisition of certain operational and manufacturing assets from En-Ko Electronic Control Systems in Izmir, Turkey. The acquisition will allow Lansinoh to directly control the manufacturing of the Lansinoh Affinity double electric breast pump, Lansinoh Affinity breast-milk storage bottles and Lansinoh ComfortFit flanges.

The new company will operate as Lansinoh Laboratories Medical Device Design and join other Lansinoh company assets, including the Lansinoh and Momma brands.

OAKLAND, Calif. — Clorox recently launched the "Quick & Dirty" cleaning guide for bachelors on its website.

CINCINNATI — HealthWarehouse.com on Tuesday announced that it has consummated two separate transactions to acquire all the online assets of Hocks Pharmacy, an online reseller of over-the-counter medications, diabetic supplies and medical equipment. HealthWarehouse.com also will merge with a newly formed subsidiary of Hocks Pharmacy.

NEW YORK — The National Advertising Division of the Council of Better Business Bureaus last week recommended that SPD Swiss Precision Diagnostics, manufacturer of the Clearblue Easy Digital home pregnancy test, modify its advertising to clarify to consumers that the test only delivers completely “certain” results on or after the day of a consumer’s expected menstrual period.

HARRISBURG, Pa. — The Pennsylvania Department of Health on Friday announced it would be distributing free nicotine replacement therapy kits beginning on Valentine's Day, Feb. 14, to help Pennsylvanians who want to give up tobacco “in the name of love.”

Under the Quit for Love campaign, the kits will be available through the state's Free Quitline (1-800-QUIT-NOW) for approximately six to eight weeks, or while supplies last.

PHILADELPHIA — GlaxoSmithKline has changed prescribing information on the labeling for one of its Type 2 diabetes drugs to reflect new restrictions on the drug’s use, the drug maker said.

GSK said it revised the labeling for Avandia (rosiglitazone) to take into account the risks of heart attacks and heart failure in patients taking the drug.

The FDA moved to restrict access to Avandia last year and required GSK to create a risk evaluation and mitigation strategy for the drug.

PALM BEACH GARDENS, Fla. — AccuDial Pharmaceutical earlier this month announced it has developed a new patent-pending line of child-proof container enclosure systems, designed to reduce the accidental or unsupervised ingestion of liquid over-the-counter and prescription medications.